[Metastatic lung adenocarcinoma. Nivolumab as second line treatment: between unresolved issues and promising future. A case report.]

In recent years immunotherapy has become a fundamental part of the treatment of many solid tumors, including non-small cell lung cancer (NSCLC). With the results of trials investigating the role of monoclonal antibodies against immuno-checkpoints in particular, today these drugs have become part of everyday clinical practice, even though many questions still remain unresolved (optimal duration of treatment, prognostic and predictive role of biomarkers, management of immuno-related toxicity). Here we report the case of our patient with diagnosis of metastatic lung adenocarcinoma "non oncogene driven" successfully treated in second line with nivolumab, analyzing the problems and the questions most frequently evidenced during treatment with these new molecules.